XML 34 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Nature of Business - Additional Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Cash, cash equivalents and short-term investments $ 19,100       $ 19,100    
Net income (3,954) $ 130 $ (6,304) $ (19,288) (3,824) $ (25,592)  
Accumulated deficit (149,888)       (149,888)   $ (146,064)
Acceleration of stock awards         10,500    
Severance and termination benefit expense         5,700    
Consideration Transferred         29,400    
Total operating expenses 6,529   6,583   12,296 28,923  
Fair value adjustment of warrant liability         7,890 1,146  
Non operating interest income 275   $ 279   582 $ 163  
Cash and cash equivalents $ 5,056       5,056   $ 5,530
Private Placement              
Gross proceeds from the private placement         20,400    
Net proceeds from private placement         19,000    
Commissions and other transaction expenses         $ 1,400    
CalciMedica              
Percentage of ownership of common stock 72.00%       72.00%    
Graybug              
Percentage of ownership of common stock 28.00%       28.00%    
Convertible Debt [Member]              
Proceeds from issuance of convertible notes         $ 8,600    
Preferred and Common stock [Member]              
Total net proceeds         $ 131,700